Inflammatory bowel disease

Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

F Schnitzler¹, H Fidder¹, M Ferrante¹, M Noman¹, I Arijs¹, G Van Assche¹, I Hoffman², K Van Steen³, S Vermeire¹, P Rutgeerts¹

¹ Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
² Department of Paediatric Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
³ Department of Electrical Engineering and Computer Science-Montefiore Institute, University of Liege, Belgium

Professor P Rutgeerts, Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; paul.rutgeerts{at}uz.kuleuven.be

Background and aims: This observational study assessed the long-term clinical benefit of infliximab (IFX) in 614 consecutive patients with Crohn’s disease (CD) from a single centre during a median follow-up of 55 months (interquartile range (IQR) 27–83).

Methods: The primary analysis looked at the proportion of patients with initial response to IFX who had sustained clinical benefit at the end of follow-up. The long-term effects of IFX on the course of CD as reflected by the rate of surgery and hospitalisations and need for corticosteroids were also analysed.

Results: 10.9% of patients were primary non-responders to IFX. Sustained benefit was observed in 347 of the 547 patients (63.4%) receiving long-term treatment. In 68.3% of these, treatment with IFX was ongoing and in 31.7% IFX was stopped, with the patient being in remission. Seventy patients (12.8%) had to stop IFX due to side effects and 118 (21.6%) due to loss of response. Although the yearly drop-out rates of IFX in patients with episodic (10.7%) and scheduled treatment (7.1%) were similar, the need for hospitalisations and surgery decreased less in the episodic than in the scheduled group. Steroid discontinuation also occurred in a higher proportion of patients in the scheduled group than in the episodic group.

Conclusions: In this large real-life cohort of patients with CD, long-term treatment with IFX was very efficacious to maintain improvement during a median follow-up of almost 5 years and changed disease outcome by decreasing the rate of hospitalisations and surgery.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Balancing the risks and benefits of prolonged use of infliximab

Jürgen Schölmerich
Gut 2009 58: 477-478. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Scholmerich, J. (2009). Balancing the risks and benefits of prolonged use of infliximab. Gut 58: 477-478 [Full Text]